Join the PrEPVacc team and AVAC as we review the status of the PrEPVacc trial. PrEPVacc, a 3-in-1 trial testing two different vaccine candidates (plus placebo arm) and two daily oral PrEP regimens, recently discontinued vaccinations in the trial due to an independent data review board’s conclusion that the vaccines were having no effect in preventing HIV infection. On this call, we will review key aspects of PrEPVacc, including its innovative study design, implementation, integrated social science, and data analysis plans. We look forward to an engaging conversation about what we’ve learned from PrEPVacc, what we can still learn, and what this may mean for the HIV prevention field. Register here.

• PrEPVacc Trial Design: Sheena McCormack, PrEPVacc Project Lead, MRC Clinical Trials Unit, University College London, UK
• Trial Implementation and Baseline Data: Eugene Ruzagira, PrEPVacc Trial Director, MRC/UVRI & LSHTM Uganda Research Unit
• Integrated Social Science: Rachel Kawuma, PrEPVacc Social Scientist, MRC/UVRI & LSHTM Uganda Research Unit
• Analysis Plan: Sheila Kansiime, PrEPVacc Statistician, MRC/UVRI & LSHTM Uganda Research Unit

Are you hosting an event soon? Share your event with us by emailing events@globalhealth.org. And, stay up-to-date with the news from the global health community by signing up for our monthly newsletter.